YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.

ABSTRACT:

Background

Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer with exceedingly poor prognosis, and chemoresistance is a huge challenge for treatment. N6-methyladenosine (m⁶ A) modification plays an important role in the progression and chemoresistance of cancers. We aimed to investigate the oncogenic function and therapeutic significance of the m⁶ A binding protein, YTH domain family 2 (YTHDF2), in ICC progression and cisplatin-based chemotherapy.

Methods

Several independent data sets were used to assess the expression of YTHDF2 in ICC, particularly in chemoresistant ICC. Knockdown and overexpression were used to evaluate the effects of YTHDF2 on tumourigenesis and cisplatin response in ICC. Multi-omics sequencing was performed to identify ta

SUBMITTER: Huang CS 

PROVIDER: S-EPMC9191870 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature